pmcMMWR Morb Mortal Wkly RepMMWR Morb Mortal Wkly RepWRMorbidity and Mortality Weekly Report0149-21951545-861XCenters for Disease Control and Prevention353248828956336mm7112a410.15585/mmwr.mm7112a4ErratumErratum: Vol. 71, No. 102532022253202225320227112474474https://creativecommons.org/publicdomain/zero/1.0/All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.AbbottA , MontgomerySP , ChanceyRJ . Characteristics and adverse events of patients for whom nifurtimox was released through CDC-sponsored investigational new drug program for treatment of Chagas disease—United States, 2001–2021. MMWR Morb Mortal Wkly Rep 2022;71:371–4. 10.15585/mmwr.mm7110a2

In the report, “Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2001–2021,” on page 371, the 11th sentence in the first paragraph should have read, “On August 6, 2020, the Food and Drug Administration (FDA) announced approval of a nifurtimox product, Lampit (Bayer), for treatment of Chagas disease in patients aged <18 years weighing ≥5.5 lbs (≥2.5 kg).”